跳到正文
原文
Endpoints News 生物医药· Max Gelman·· 2026-09-30AI 评分45

#EADV26:Merck 公布 Prometheus 药物皮肤病适应症中期数据

#EADV26: Merck shows off mid-stage win for Prometheus drug in skin condition

AI 导读

Merck 在 EADV26 上公布其 108 亿美元收购 Prometheus Biosciences 核心药物在一种皮肤疾病中的中期数据。原文未披露具体药名、研究期别、样本量及疗效终点数值。

正文

Mer­ck de­tailed some mid-stage da­ta in a de­bil­i­tat­ing skin con­di­tion on Wednes­day morn­ing for the cen­ter­piece of its $10.8 bil­lion Prometheus Bio­sciences ac­qui­si­tion.

Both the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news